Statements (36)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Antihero
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:2015
gptkb:FDA |
| gptkbp:brand |
Savaysa
|
| gptkbp:chemical_formula |
C21 H25 N3 O5 S
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
active bleeding
severe renal impairment |
| gptkbp:developed_by |
gptkb:Daiichi_Sankyo
|
| gptkbp:dosage_form |
gptkb:tablet
15 mg 30 mg 60 mg |
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
edoxaban
|
| gptkbp:indication |
venous thromboembolism
non-valvular atrial fibrillation |
| gptkbp:interacts_with |
NSAIDs
antiplatelet agents other anticoagulants |
| gptkbp:lifespan |
10 to 14 hours
|
| gptkbp:mechanism_of_action |
factor Xa inhibitor
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:side_effect |
gptkb:anemia
nausea bleeding liver enzyme elevation |
| gptkbp:used_for |
preventing stroke
treating deep vein thrombosis treating pulmonary embolism |
| gptkbp:weight |
453.56 g/mol
|
| gptkbp:bfsParent |
gptkb:factor_Xa
gptkb:Andexxa gptkb:Andexanet_alfa |
| gptkbp:bfsLayer |
7
|